Lantheus Holdings (LNTH) SEC Filings: History & Chart

Lantheus Holdings, Inc.(LNTH)

Drug Manufacturers - Specialty & Generic · Bedford, MA

$100.00-0.19 (-0.19%)

Delayed quote: Oct 6, 2026, 3:50 PM EDT

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.

Bedford, MA

1,193 employees

www.lantheus.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Mary Anne Heino

View full financials

Form	Filing Date	Accepted	Document
DEFA14A	Oct 2, 2026	Oct 2, 2026	View filing
8-K	Oct 2, 2026	Oct 2, 2026	View filing
SC 13D/A	Sep 23, 2026	Sep 23, 2026	View filing
DEFA14A	Sep 21, 2026	Sep 21, 2026	View filing
8-K	Sep 21, 2026	Sep 21, 2026	View filing
DEFA14A	Sep 17, 2026	Sep 16, 2026	View filing
4	Sep 8, 2026	Sep 8, 2026	View filing
DEFM14A	Sep 8, 2026	Sep 8, 2026	View filing
4	Sep 4, 2026	Sep 4, 2026	View filing
SC 13D/A	Sep 4, 2026	Sep 4, 2026	View filing
SC 13G	Sep 4, 2026	Sep 4, 2026	View filing
SC 13D	Sep 4, 2026	Sep 4, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
S-8	Sep 2, 2026	Sep 2, 2026	View filing
PREM14A	Aug 26, 2026	Aug 26, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
DEFA14A	Aug 13, 2026	Aug 13, 2026	View filing
SC 13G/A	Aug 13, 2026	Aug 13, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
DEFA14A	Aug 4, 2026	Aug 4, 2026	View filing
DEFA14A	Aug 4, 2026	Aug 3, 2026	View filing
8-K	Aug 4, 2026	Aug 3, 2026	View filing
DEFA14A	Aug 3, 2026	Aug 3, 2026	View filing
DEFA14A	Aug 3, 2026	Aug 3, 2026	View filing
8-K	Aug 3, 2026	Aug 3, 2026	View filing
SC 13G	Jul 31, 2026	Jul 31, 2026	View filing

SEC Filings

Recent Filings